Sildenafil citrate + Sildenafil citrate + Placebo + Sildenafil citrate

Phase 3Completed
1 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pulmonary Arterial Hypertension, Children

Conditions

Pulmonary Arterial Hypertension, Children

Trial Timeline

Aug 1, 2003 → Jun 1, 2008

About Sildenafil citrate + Sildenafil citrate + Placebo + Sildenafil citrate

Sildenafil citrate + Sildenafil citrate + Placebo + Sildenafil citrate is a phase 3 stage product being developed by Pfizer for Pulmonary Arterial Hypertension, Children. The current trial status is completed. This product is registered under clinical trial identifier NCT00159913. Target conditions include Pulmonary Arterial Hypertension, Children.

What happened to similar drugs?

20 of 20 similar drugs in Pulmonary Arterial Hypertension, Children were approved

Approved (20) Terminated (1) Active (0)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00159913Phase 3Completed

Competing Products

20 competing products in Pulmonary Arterial Hypertension, Children

See all competitors
ProductCompanyStageHype Score
AP01Avalyn PharmaceuticalsPhase 2
32
macitentan 10 mgBML, Inc.Phase 3
32
tadalafil + tadalafilEli LillyPhase 3
40
CS1 AdministrationCereno ScientificPhase 2
29
CS1Cereno ScientificPre-clinical
24
TX000045- Dose A + TX000045- Dose B + PlaceboTectonic TherapeuticPhase 2
36
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
25
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 2
32
Satralizumab (Genetical Recombination)Chugai PharmaceuticalPhase 2
39
DS-1040b + Placebo + EnoxaparinDaiichi SankyoPhase 1/2
32
DS-9231 + PlaceboDaiichi SankyoPhase 2
27
RegadenosonAstellas PharmaPre-clinical
18
Reldesemtiv + PlaceboAstellas PharmaPhase 2
35
MonteplaseEisaiApproved
43
lysozyme 90 mg + PlaceboEisaiApproved
43
Prednisolone + VoriconazoleCiplaPhase 2/3
38
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)Eli LillyPhase 2
35
tadalafil and ambrisentan upfront combination therapyEli LillyApproved
43